Genomic AI Opens the Door to the Future of Medicine [Fujitsu's Challenge].

In recent years, AI technology has undergone remarkable evolution and is revolutionizing various fields. Fujitsu has also been actively engaged in research and development of AI technology, and has achieved significant results, particularly in the field of "genomic AI.

Genomic AI is a technology that combines whole genetic information (genome) and AI, and is expected to drive innovation in the medical field, including cancer diagnosis and treatment, personalized medicine, and drug discovery.
AI is attracting attention in the IT field, but it is also compatible with medicine, and there are high expectations for AI applications in the medical field.

Fujitsu's Focus on "Pathogenicity Estimation" and "Multimodal Genomics

Fujitsu is focusing on two technologies in genomic AI in particular: "pathogenicity estimation" and "multimodal genomics.

Pathogenicity estimation is a technology that precisely measures cancer-causing gene mutations in a patient's genome and elucidates how these mutations are involved in the development of cancer. This technology is being developed in collaboration with the Institute of Medical Science of the University of Tokyo, and its usefulness has been recognized by the publication of the world's first research results in an academic journal.

Multimodal genomics is a technology to construct a large-scale integrated database by converting genomic information and pathological image data, which have conventionally been handled separately, into knowledge graphs, respectively, and linking related data and knowledge together. This technology is being developed in collaboration with the Barcelona Supercomputing Center (BSC) in Spain, and has achieved the world's highest accuracy rate of 92.1% in classifying lung cancer types.

Innovations brought about by Genomic AI: Contributions to Personalized Medicine and Drug Discovery

Genomic AI is expected not only to improve the accuracy of cancer diagnosis and treatment, but also to contribute to personalized medicine and drug discovery.

Personalized medicine is medicine in which the optimal treatment is determined based on an individual's genome information. Genomic AI enables the development of more effective and safer treatments by analyzing the genomic information of each individual.

Drug discovery is the development of new medicines. Genomic AI enables the development of new drugs more efficiently and effectively than ever before by analyzing the genes and proteins that cause diseases.

Fujitsu's Strengths: Seven Years of Experience and Knowledge Graph Technology

Fujitsu boasts more than seven years of experience in genomic AI research, with particular strength in knowledge graph technology. Knowledge graph is a technology that systematically integrates various types of data and expresses knowledge. By utilizing this technology in genome AI, more accurate analysis and prediction will become possible.

Conclusion: Genomic AI opens up the possibilities of future medicine

Fujitsu's genomic AI research is expected to greatly accelerate innovation in the medical field and contribute to the health and well-being of many people. Fujitsu will continue to actively promote genome AI research and contribute to the realization of future medicine.

Reference information

Fujitsu Limited Press Release: https://activate.fujitsu/en/key-technologies/ai

Institute of Medical Science, The University of Tokyo: http://www.ims.u-tokyo.ac.jp/

Barcelona Supercomputing Center: https://www.bsc.es/